Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Can-Fite Biopharma Ltd ADR 26 BEN GURION STREET RAMAT GAN L3 5257346 ISR

www.canfite.com P: 972-3924-1114

Description:

Can Fite Biopharma Ltd. is a biopharmaceutical company. It is focused on developing drugs for the treatment of cancer and autoimmune inflammatory diseases. The Company's lead drug candidate, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. Its CF102 drug candidate is being developed for the treatment of liver diseases and its CF602 drug is being developed for the treatment of inflammation and sexual dysfunction. Can Fite Biopharma Ltd. is based in Petach Tikva, Israel.

Key Statistics

Overview:

Market Capitalization, $K 7,187
Enterprise Value, $K 2,907
Shares Outstanding, K 3,540
Annual Sales, $ 740 K
Annual Net Income, $ -7,630 K
Last Quarter Sales, $ 160 K
Last Quarter Net Income, $ -1,650 K
EBIT, $ -2,710 K
EBITDA, $ -8,180 K
60-Month Beta 1.58
% of Insider Shareholders 0.80%
% of Institutional Shareholders 21.00%
Float, K 3,512
% Float 99.20%
Short Volume Ratio 0.72

Growth:

1-Year Return 8.85%
3-Year Return -90.05%
5-Year Return -96.87%
5-Year Revenue Growth -80.63%
5-Year Earnings Growth 96.49%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.31 on 03/28/24
Latest Earnings Date 06/06/24
Earnings Per Share ttm -1.79
EPS Growth vs. Prev Qtr 27.91%
EPS Growth vs. Prev Year 72.07%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 01/09/23

CANF Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -113.75%
Return-on-Assets % -69.91%
Profit Margin % -1,031.08%
Debt/Equity 0.00
Price/Sales 9.96
Price/Cash Flow N/A
Price/Book 1.17
Book Value/Share 1.76
Interest Coverage -1.58
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar